- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03498040
Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors (CRUSOE-NETs)
Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors Carcinoid Heart Disease (CHD): An Observational French Multi-Centre Cohort Study CRUSOE - NETs (CaRdiac UltraSonic OutcomEs - NETs)
Carcinoid Heart Disease (CHD) is a rare form of heart disease, occurring in over 50% of the patients with carcinoid syndrome. Pathophysiology, prognostic factors of development of Carcinoid Heart Disease and progression of disease remain unclear.
This observational multicenter cohort study is designed to study the occurrence of Carcinoid Heart Disease in patients with differentiated carcinoid tumors, to describe numerous factors influencing the occurrence, severity, progression and long-term survival of patients with Carcinoid Heart Disease. Basic informations and detailed diagnosis informations (oncological and cardiac parameters), are collected by professional doctors. Clinical outcomes (onset of Carcinoid Heart Disease, cardiac surgery, related death) will be followed up every year or every six/three months if clinically indicated.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Catherine LOMBARD-BOHAS, Dr
- Phone Number: +33 04 72 11 91 67
- Email: catherine.lombard@chu-lyon.fr
Study Contact Backup
- Name: Laurent FRANCOIS, Dr
- Phone Number: +33 04 72 35 71 62
- Email: laurent.francois@chu-lyon.fr
Study Locations
-
-
-
Lyon, France, 69437
- Hôpital Edouard HERRIOT, Institut du Cancer - Hospices Civils de Lyon
-
Contact:
- Catherine LOMBARD-BOHAS, Dr
- Phone Number: +33 04 72 11 91 67
- Email: catherine.lombard@chu-lyon.fr
-
Contact:
- Laurent FRANCOIS, Dr
- Phone Number: +33 04 72 35 71 62
- Email: laurent.francois@chu-lyon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients over 18 years
- Patients followed in a NeuroEndocrine Tumor center with a reference cardiologist
Patient with:
- Histologically documented metastatic well-differentiated ileum neuroendocrine tumor or
- Histologically documented metastatic well-differentiated bronchial neuroendocrine tumor, or
- Histologically documented well differentiated neuroendocrine tumor, regardless of the primitive site or unknown primitive site and presenting a carcinoid syndrome and / or an elevation of urinary 5HIAA > 2 fold the upper limit of normal range
- Information given to the patient and his documented non-opposition
Exclusion Criteria:
- Poorly differentiated neuroendocrine carcinoma
- Patient unable / unwilling to follow the cardiac monitoring recommended by good practice data
- Any medical, geographical, sociological, psychological or legal situation that does not allow the patient to complete the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with or at risk of carcinoid heart disease
|
Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease. In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease. Investigators collect the data of clinical parameters (flushes, diarrhea, …) biological parameters (urinary 5HIAA, NT-ProBNP …) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Carcinoid Heart Disease
Time Frame: 10 years (at the end of study)
|
Percentage of patients with carcinoid heart disease at diagnosis and during follow-up (carcinoid heart disease diagnosis will be assessed by an annual echocardiography).
|
10 years (at the end of study)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac surgery
Time Frame: 10 years (at the end of study)
|
Percentage of patients requiring cardiac surgery for the cardiac carcinoid heart disease
|
10 years (at the end of study)
|
5HIAA levels
Time Frame: 10 years (at the end of study)
|
Correlation between urinary 5HIAA levels at diagnosis and occurrence of carcinoid heart disease
|
10 years (at the end of study)
|
Survival
Time Frame: 10 years (at death or at the end of study)
|
Overall survival in patents with and without carcinoid heart disease
|
10 years (at death or at the end of study)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Malignant Carcinoid Syndrome
- Heart Diseases
- Neuroendocrine Tumors
- Carcinoid Tumor
- Carcinoid Heart Disease
Other Study ID Numbers
- 69HCL17_0700
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoid Heart Disease
-
Queen Mary University of LondonRoyal Free Hospital NHS Foundation TrustActive, not recruitingCarcinoid Syndrome | Carcinoid Heart Disease | Tricuspid Regurgitation | Tricuspid Valve DiseaseUnited Kingdom
-
European Organisation for Research and Treatment...IpsenWithdrawn
-
King's College Hospital NHS TrustAdvanced Accelerator ApplicationsNot yet recruitingCarcinoid Tumor | Carcinoid Syndrome | Carcinoid Heart Disease
-
Novartis PharmaceuticalsCompletedSymptomatic Refractory Resistant Carcinoid DiseaseUnited Kingdom, Belgium, Italy, Singapore, Austria, France, Israel, Sweden, Germany, Spain, Canada, Argentina, Poland, United States, Brazil, Norway
-
Crinetics Pharmaceuticals Inc.Active, not recruitingCarcinoid Tumor | Carcinoid Syndrome | Carcinoid | Carcinoid Tumor of Ileum | Carcinoid Tumor of Cecum | Carcinoid Syndrome Diarrhea | Carcinoid Intestine Tumor | Carcinoid Tumor of Liver | Carcinoid Tumor of PancreasUnited States, Brazil, Argentina, Canada, Mexico, Peru, Poland
-
IpsenTerminatedCarcinoid SyndromeSpain, Belgium, Ireland, Czechia, Israel, France, United Kingdom, Latvia, Germany, Russian Federation, Slovakia, Italy, Netherlands, Finland, Austria, Poland, Sweden, Ukraine
-
IpsenTerminatedMalignant Carcinoid SyndromeUnited States
-
Lexicon PharmaceuticalsCompletedCarcinoid SyndromeGermany, United Kingdom
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompleted
-
IpsenCompletedCarcinoid SyndromeUnited States, Turkey, Brazil, India, Ukraine, South Africa, Czechia, Latvia, Poland, Russian Federation, Serbia
Clinical Trials on Study of the occurrence of Carcinoid Heart Disease
-
Centre Hospitalier Universitaire, AmiensWithdrawnInterest of Pulse Wave Velocity Measurement as a Predictor of Severity of Aortic Stenosis (VOPRABIO)Aortic Stenosis | Pulse WaveFrance
-
University of British ColumbiaUnknownChronic Obstructive Lung DiseaseCanada
-
Brooklyn College of the City University of New...National Heart, Lung, and Blood Institute (NHLBI); Department of Health and...CompletedStroke | Cardiovascular Disease | Heart Disease
-
Hospices Civils de LyonRecruitingCardiomyopathies | Left Ventricular Hypertrophy | Hypertension Arterial | HypokineticFrance
-
University Hospital, GhentCompleted
-
University College, LondonUnknownDementia, Alzheimer, Electronic Health Records, Hospitalizations, Epidemiology, Comorbidity, United Kingdom, Incidence, Mortality, Cause of Death
-
University College, LondonUnknownAtrial Fibrillation | Epidemiology
-
Rennes University HospitalCompletedSupraventricular ArrhythmiasFrance
-
Centre Hospitalier Universitaire de NīmesCompletedAntiphospholipid Antibody Syndrome in PregnancyFrance
-
German Heart InstituteUniversity of Sheffield; Sheffield Teaching Hospitals NHS Foundation Trust; University... and other collaboratorsCompletedHeart Valve Diseases